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Gain-of-function mutations in fibroblast growth factor (FGF) receptors result in chondrodysplasia and craniosynostosis syndromes, highlighting
the critical role for FGF signaling in skeletal development. Although the FGFRs involved in skeletal development have been well characterized,
only a single FGF ligand, FGF18, has been identified that regulates skeletal development during embryogenesis. Here we identify Fgf9 as a second
FGF ligand that is critical for skeletal development. We show that Fgf9 is expressed in the proximity of developing skeletal elements and that Fgf9-
deficient mice exhibit rhizomelia (a disproportionate shortening of proximal skeletal elements), which is a prominent feature of patients with
FGFR3-induced chondrodysplasia syndromes. Although Fgf9 is expressed in the apical ectodermal ridge in the limb bud, we demonstrate that the
Fgf9−/− limb phenotype results from loss of FGF9 functions after formation of the mesenchymal condensation. In developing stylopod elements,
FGF9 promotes chondrocyte hypertrophy at early stages and regulates vascularization of the growth plate and osteogenesis at later stages of skeletal
development.
© 2007 Elsevier Inc. All rights reserved.Keywords: Fibroblast growth factor 9 (FGF9); Skeletal development; Growth plate; Chondrocyte; Osteoblast; Periosteum; Perichondrium; Vascular developmentIntroduction
Fibroblast growth factor (FGF) signaling is essential for
vertebrate limb development, from the initial formation and
outgrowth of the limb bud to patterning and growth of the
skeletal elements (Mariani and Martin, 2003; Min et al., 1998;
Niswander, 2003;Ohuchi et al., 1997). The early phases of limb
induction require the expression of Fgf10 in lateral plate meso-
derm, which activates FGFR2b in the overlying epithelium.
Subsequently, Fgf8 is expressed in the apical ectodermal ridge
(AER) along with Fgfs 4, 9 and 17 (Colvin et al., 1999; Martin,
1998; Maruoka et al., 1998). Signals emanating from this spe-
cialized ectoderm are required for proximal-to-distal limb out-⁎ Corresponding author.
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doi:10.1016/j.ydbio.2007.04.048growth, as well as maintenance of mesenchymal gene
expression in the limb bud. Previous studies have shown that
conditional inactivation of Fgf8 (Fgf8cko) in the AER at early
stages results in hypoplasia or agenesis of proximal limb
elements as well as less severe abnormalities in the intermediate
and distal elements (Lewandoski et al., 2000; Moon and
Capecchi, 2000). Conditional inactivation of both Fgfs 4 and 8
(Fgf4/8cko) in the AER ultimately results in limb agenesis;
however, small limb buds do form initially. The defects in the
proximal skeletal elements of the Fgf8cko and Fgf4/8cko animals
are thought to result from the dramatic increase in apoptosis
observed in the proximal limb bud mesenchyme (Boulet et al.,
2004; Sun et al., 2002).
After limb bud initiation and outgrowth, development of the
appendicular skeleton occurs via endochondral ossification,
with cartilage anlagen prefiguring the future bone (Erlebacher
et al., 1995; Karsenty and Wagner, 2002). Following formation
of mesenchymal condensations, cells within these condensa-
tions differentiate into proliferating chondrocytes which ela-
borate an extracellular matrix rich in type II collagen, while
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chondrium. As the cartilaginous template elongates, chondro-
cytes within the anlagen mature and hypertrophy, secreting a
matrix rich in type X collagen. Concomitantly, skeletal vascu-
larization is stimulated by angiogenic growth factors such as
vascular endothelial growth factors (VEGF) (Gerber et al.,
1999; Zelzer and Olsen, 2005) produced in the perichondrium
and hypertrophic cartilage. These changes allow perichondrial
angiogenesis to occur and, subsequently, invasion of blood
vessels, osteoblasts, and osteoclasts into the avascular
cartilaginous template to form the primary ossification center.
In a separate, but related, process, osteoprogenitor cells in the
perichondrium differentiate into osteoblasts to form cortical
bone. These events: chondrogenesis, vascularization and
osteogenesis, are coordinated by multiple signaling molecules
including IHH, PTHrP, VEGF and FGF to regulate skeletogen-
esis (de Crombrugghe et al., 2001; Karsenty and Wagner,
2002; Ornitz and Marie, 2002; Zelzer and Olsen, 2005).
Multiple human skeletal dysplasia syndromes result from
activating mutations in FGF receptors, highlighting the critical
role for FGF signaling in bone development. For example,
chondrodysplasias such as achondroplasia, hypochondroplasia
and thanatophoric dysplasia are due to mutations in FGFR3
(Bellus et al., 1995; Rousseau et al., 1994; Shiang et al., 1994;
Tavormina et al., 1995). The limb dysmorphology of these
patients is characterized by rhizomelic shortening, with prox-
imal elements affected more severely than intermediate and
distal elements. Various craniosynostosis syndromes are caused
by activating mutations in FGFR1–3 and result in premature
fusion of the cranial sutures (Britto et al., 2001; Cohen, 2000;
Morriss-Kay and Wilkie, 2005; Wilkie, 1997, 2000). Afflicted
patients also exhibit variable abnormalities in limb development
in addition to their calvarial deformities. Despite the identifica-
tion and functional characterization of the FGFRs involved in
skeletogenesis, to date only two of the 22 known FGFs, FGF2
and FGF18, have been shown to have functional roles in
skeletal development.
Fgf18 is expressed in the perichondrium and joint spaces and
regulates early stages of cartilage development by promoting
chondrocyte proliferation and differentiation while, at later
stages, FGF18 functions to inhibit chondrogenesis by signaling
to FGFR3. Additionally, FGF18 promotes skeletal vasculariza-
tion by inducing Vegf expression and positively regulates osteo-
genesis by signaling to FGFR 1 and 2 in the developing peri-
chondrium/periosteum (Liu et al., 2002, 2007; Ohbayashi et al.,
2002). Besides Fgf18, expression of Fgfs 7, 8 and 17 has also
been observed in the perichondrium; however, gene targeting
experiments have not elucidated roles for these ligands in
skeletal development (Finch et al., 1995; Mason et al., 1994; Xu
et al., 1999). Fgf2 expression has been demonstrated in proli-
ferating and prehypertrophic chondrocytes, periosteal cells and
osteoblasts (Hurley et al., 1994, 1999; Sabbieti et al., 1999,
2005; Sullivan and Klagsbrun, 1985). Mice lacking Fgf2 have
defects in osteogenesis, which result in aberrant trabecular bone
formation (Montero et al., 2000). The identification of add-
itional endogenous FGF ligand(s) for FGFRs expressed in bone
has been problematic, likely due to functional redundancy be-tween ligands or, alternatively, activity restricted to specific
skeletal elements or to limited developmental stages.
Fgf9 is expressed in the AER of the developing limb bud and
in migrating myoblasts (Colvin et al., 1999). Fgf9 transcripts
have also been observed surrounding and within precursor ske-
letal elements at E12.5 and E14.5 (Garofalo et al., 1999). Here
we show Fgf9 expression localized to the perichondrium/perio-
steum, trabecular bone, muscle and loose mesenchyme sur-
rounding developing bone. Mice lacking Fgf9 (Fgf9−/−) exhibit
rhizomelia, a prominent limb patterning defect observed in
patients afflicted with achondroplasia. In Fgf9-deficient mice,
the hindlimb femora are affected more severely than the fore-
limb humeri. The Fgf9−/− limb phenotype can be interpreted as
a consequence of loss of Fgf9 expression in the AER resulting
in a skeletal patterning defect that primarily affects mesench-
ymal condensations, or loss of Fgf9 expression at later stages of
skeletogenesis directly affecting chondrogenesis, osteogenesis
and/or vascularization of proximal skeletal elements. Here we
demonstrate that Fgf9−/− mice have normal limb bud develop-
ment and mesenchymal condensations, but in stylopod
elements, decreased chondrocyte proliferation, delayed initia-
tion of chondrocyte hypertrophy and abnormal osteogenesis
secondary to defects in skeletal vascularization.Materials and methods
Skeletal preparations and bone morphometric analysis
Skeletons were prepared as described previously (Colvin et al., 1996) using
Alizarin red S and Alcian blue (Sigma) staining to visualize mineralized bone
and cartilage, respectively. Lengths of individual bones were measured at E18.5
using Canvas X (ACD Systems) software.
Generation of mice
Fgf9−/− and Fgfr3−/− mice were generated as described (Colvin et al., 1996;
Colvin et al., 2001). Conditional alleles for FGFR1 and FGFR2 have been
previously described (Pirvola et al., 2002; Yu et al., 2003). Mice homozygous
for conditional alleles of both FGFR1 and FGFR2 (Fgfr1flox/flox;Fgfr2flox/flox)
were crossed with mice carrying one copy of Dermo-1-cre (Yu et al., 2003) and
heterozygous for null alleles of FGFR1 and FGFR2 (Fgfr1Δ/+;Fgfr2Δ/+;cre/+)
to obtain litters containing wild-type, Fgfr1cko and Fgfr2cko embryos. Note that
Fgfr1 and Fgfr2 single CKO embryos are also missing one functional allele of
FGFR2 and FGFR1, respectively.
Histological analysis, immunohistochemistry and in situ hybridization
Tissues were fixed in 4% paraformaldehyde. Histomorphometry was carried
out on hematoxylin and eosin (H&E)-stained 5 μm paraffin sections using
AxioVision 3.0 software (Zeiss). Hypertrophic zone heights were measured
along the midline of the distal femoral and proximal tibial growth plates at E17.5
and E18.5. At least 3 sections were measured for each embryo. Mineralized bone
was visualized by von Kossa staining with methyl green counterstaining. For
PECAM (CD31) immunohistochemistry, embryos were fixed in 4% parafor-
maldehyde followed by 20% sucrose infiltration. Tissues were embedded in
OCT (Tissue-Tek®) and 10-μm cryostat sections were made. Sections were
fixed in 0.2% glutaraldehyde prior to peroxidase blocking with 3% H2O2 in
methanol. The primary antibody was anti-PECAM (BD PharMingen).
Secondary antibody was biotinylated anti-rat IgG (BD PharMingen). Immunor-
eactivity detection was performed using a streptavidin–biotin–peroxidase
complex (sABC-HRP, DakoCytomation K0377) and DAB (Zymed). Sections
were counterstained with hematoxylin. Whole-mount in situ hybridization was
Fig. 1. Proximal limb development in Fgf9−/−mice. (A, B) Skeletal preparations
of control and Fgf9−/− forelimbs (A) and hindlimbs (B) at P0. Note enlarged
deltoid tuberosity (arrows) in the Fgf9−/− humerus. The Fgf9−/− femur is
significantly shorter than control with a smaller region of Alizarin red staining.
The third trochanter is missing on the lateral aspect of the femur (arrows in panel
B). (C) Higher magnification of femora from (B) to show absence of third
trochanter (arrow) in Fgf9−/− mice. (D) Comparison of femur to tibia length
ratios between control and Fgf9−/− hindlimbs shows statistically significant
reduction in length ratio for Fgf9−/− limb. *Student's T test, n=3, p=0.013.
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performed as described (Naski et al., 1998).
Analysis of cell proliferation and apoptosis
Anti-bromodeoxyuridine (BrdU) immunohistochemistry was carried out as
described (Naski et al., 1998). BrdU-positive nuclei of reserve and proliferating
chondrocytes were counted and the area of the reserve and proliferating
chondrocyte zones was measured using ImageJ 1.36b software (NIH). The
number of BrdU-positive nuclei per 0.01 mm2 area was calculated for each
embryo examined. At least three sections were analyzed through a 10× objective
for each embryo. TUNEL assay was performed using the In Situ Cell Death
Detection Kit, POD (Roche) per manufacturer's instructions.
Embryonic limb explant cultures
Forelimb cartilage was dissected from E14.5 VEGF-LacZ mouse embryos
(Miquerol et al., 1999) and placed at the air-fluid interface on Transwell filters
(Corning) containing DMEM with 10% fetal calf serum (GibcoBRL), antibiotic
antimycotic solution (Sigma) and 2 μg/ml heparin. Media were supplemented
with 250 ng/ml recombinant FGF10 (PeproTech), recombinant FGF9 (Pepro-
Tech) or BSA. Explants were cultured for 2 days at 37 °C/5% CO2 under
humidified conditions.
Limb explant histochemistry and immunohistochemistry
Whole-mount β-galactosidase staining was performed as described (Liu et al.,
2007). After post-fixing in 4%paraformaldehyde, the explants were infiltratedwith
20% sucrose and embedded in OCT at −20 °C for sectioning. Frozen sections
(8 μm) were mounted in toluene-based media. The contralateral limb explant was
used for PECAMwhole-mount immunohistochemistry as described (Lavine et al.,
2006). For histological analysis, 5-μm paraffin sections of stained explants were
counterstained with hematoxylin.Results
Loss of Fgf9 affects the proximal skeletal elements of the
developing limb
Comparison of Alizarin red- and Alcian blue-stained skele-
tons of E18.5 and P0 mice showed that the skeletons of Fgf9−/−
mice were approximately 10–15% smaller than littermate con-
trols. Although the general patterning of the Fgf9−/− skeletal
elements resembled that of control animals, the Fgf9−/− hind-
limb proximal elements were disproportionately shorter, while
the intermediate and distal elements of the limbs appeared un-
affected (Figs. 1A, B). Fgf9−/− mice also lacked the third tro-
chanter (Fig. 1C), normally located on the lateral aspect of the
femur (Bateman, 1954). Additionally, closer examination of the
Fgf9−/− humerus revealed an enlarged deltoid tuberosity (Fig.
1A). Thus, bone growth and patterning defects were observed in
the stylopod elements of Fgf9−/− mice. In comparison with
controls, the Alizarin red-stained region of the Fgf9−/− femur
appeared smaller, suggesting that bony mineralization was
decreased.
Morphometric analyses were performed on limb skeletal
preparations of Fgf9−/− and littermate controls at E18.5. In the
forelimb, the mutant humerus length was not significantly shor-
ter (92% of control, n=3, p=0.06). In the hindlimb, the mutant
femur length was significantly decreased (82% of control, n=3,
p=0.008). Because the entire skeleton of Fgf9−/− mice was 10–15% smaller than that of control animals, we compared ratios of
limb element lengths to determine whether the proximal ele-
ments of the limbs were disproportionately reduced compared
to the intermediate limb compartment. In the forelimb, the ratio
of humerus to radius or ulna length did not reveal a significant
difference between Fgf9−/− and control mice (data not shown).
However, the femur to tibia ratio showed a significantly smaller
hindlimb stylopod in Fgf9−/− mice compared to control (control
femur/tibia (F/T) ratio=0.96±0.03; Fgf9−/− F/T ratio=0.85±
0.04; p=0.013, n=3) (Fig. 1D).
Fgf9 expression during limb development
Previous studies have localized Fgf9 expression to the AER
of the developing limb bud at E10.5 and to skeletal myoblasts at
E10.5–E12.5 (Colvin et al., 1999). Fgf9 expression has also
been observed at later stages during skeletal development in
regions corresponding to mesenchymal condensations in the
limb at E12.5 and in mesenchyme surrounding rib condensa-
tions at E14.5 (Garofalo et al., 1999). Our examination of spatial
and temporal patterns of Fgf9 expression in the limb showed
that, at E12.5, Fgf9 was expressed in the mesenchyme sur-
rounding the cartilaginous condensations; however, its expres-
sion was excluded from the condensations (Figs. 2A, B). At
later stages of limb development, Fgf9 was expressed in the
perichondrium/periosteum, as well as in surrounding skeletal
muscle and overlying skin (Figs. 2C–F). Low levels of Fgf9
mRNA were also detectable in the primary spongiosa at this
Fig. 2. Fgf9 expression patterns in the developing limb. (A) Longitudinal section
through the hindlimb of an E12.5 embryo stained with hematoxylin and eosin
(H&E). (B) Fgf9 in situ hybridization of a nearby section to that shown in panel
A. Note Fgf9 transcripts are excluded from the condensations (f—femur, t—
tibia, a—autopod). (C) H&E staining of longitudinal section through femur and
proximal tibia at E16.5. (D) Nearby section to panel C showing Fgf9 expression
in the perichondrium/periosteum (po), trabecular bone (tb), surrounding muscle
(m) and skin (s) but not in proliferating (p) or hypertrophic (h) chondrocytes. (E)
H&E staining of a longitudinal section through the ulna (top) and radius (bottom)
at E15.5. (F) Nearby section to panel E showing Fgf9 expression in the
perichondrium/periosteum (po) and skin (s).
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multiple stages of skeletogenesis since, like Fgf18 (Liu et al.,
2002; Ohbayashi et al., 2002), this ligand is juxtaposed to
Fgfr3-expressing proliferating chondrocytes, Fgfr1-expressing
hypertrophic chondrocytes and Fgfr1 and Fgfr2-expressing
cells in the perichondrium and periosteum (Naski and Ornitz,
1998; Orr-Urtreger et al., 1991; Peters et al., 1992, 1993).
Additionally, Fgf9 expression in the skeletal musculature
surrounding bone could serve as an additional source of ligand
that may also impact skeletal development.
Loss of Fgf9 from the AER does not cause limb patterning
defects
Transgenic mice with reduced AER-FGF signaling due to a
conditional loss of Fgf8 (Fgf8cko) or a combination of Fgfs 4
and 8 (Fgf4/8cko) from the AER have shortened or absent
proximal limb elements (Boulet et al., 2004; Lewandoski et al.,2000; Moon and Capecchi, 2000; Sun et al., 2002). These mice
also had smaller limb bud sizes and decreased expression of
mesenchymal limb bud genes. Although the Fgf9−/− mice have
stylopod element defects similar to those observed in the
Fgf8cko and Fgf4/8cko mice, the Fgf9−/− limb buds appeared
normal in size between E9.5 and E11.5 (Figs. 3A–F and data
not shown). To determine whether any molecular changes were
detectable in Fgf9−/− limb buds, the expression patterns of Fgf8
and Shh were examined by whole-mount in situ hybridization.
Similar levels of Fgf8 expression were observed in Fgf9−/− and
control limb buds (Figs. 3A, B). Shh (important for anterior–
posterior (AP) patterning and AER maintenance) expression in
the posterior limb mesenchyme requires AER-FGF signaling
(Laufer et al., 1994; Niswander et al., 1994; Zuniga et al., 1999).
Shh expression levels appeared slightly decreased and diffuse in
Fgf9−/− limb buds compared to controls (Figs. 3C, D). In the
Fgf4/8cko embryos, increased apoptosis in proximal limb
mesenchyme was observed, which was hypothesized to result
in a smaller proximal mesenchymal condensation and conse-
quently smaller proximal skeletal elements. At E10.5 and
E11.5, we observed similar levels of apoptosis in the proximal
limb bud and in the AER of control and Fgf9−/− mice (Figs. 3E,
F and data not shown). Together, these data suggest that AER-
FGF function is preserved in Fgf9−/− mice and that FGFs 4, 8
and 17 can functionally compensate for any loss of FGF9
signaling.
Defects in AER-FGF signaling resulted in reduced proximal
condensation sizes during early limb development in Fgf8cko
and Fgf4/8cko mice. However, in Fgf9−/− mice, histological
sections revealed that mesenchymal condensations correspond-
ing to proximal, intermediate and distal skeletal elements ap-
peared normal in size and shape at E12.5 (Figs. 3G, H).
Although Shh expression was slightly decreased in the Fgf9−/−
limb bud, Fgf9−/− autopod elements were indistinguishable
from controls, suggesting that normal SHH signaling was pre-
sent. Additionally, Sox9, a marker of prechondrogenic conden-
sations, was expressed at control levels in Fgf9−/− limb conden-
sations (Figs. 3I, J). Levels of type II collagen (ColII)
expression in Fgf9−/− mice appeared similar to controls (Figs.
3K, L), indicating that mesenchymal cells within the condensa-
tions were undergoing chondrogenic differentiation. These data
demonstrate that mesenchymal aggregation and condensation,
as well as early stages of chondrogenic differentiation, are not
significantly altered during the initial stages of limb develop-
ment in Fgf9−/− mice and suggest that loss of Fgf9 from the
AER does not cause the observed rhizomelic phenotype.
Delayed skeletogenesis in Fgf9−/− proximal limb elements
Histological analyses at later stages of limb development
revealed delayed endochondral ossification of fore- and
hindlimb stylopod elements in mice lacking Fgf9 (Figs. 4A–
D, G–J). Normally, at E15.5, the primary ossification center in
the humerus has formed; however, at this stage, the diaphysis of
the Fgf9−/− humerus contained predominantly hypertrophic
chondrocytes with a narrow zone of vascularization (Figs. 4A,
B). In the hindlimb at E15.5, blood vessels were visible in the
Fig. 3. Loss of Fgf9 from the AER does not affect limb bud development. (A, B) Fgf8 expression in the AER of E10.5 control (A) and Fgf9−/− (B) hindlimb buds
visualized by whole-mount in situ hybridization (WISH). (C, D) Shh expression in the AER of E10.5 control (C) and Fgf9−/− (D) hindlimb buds visualized by WISH.
(A–D) Dorsal view, anterior to the left, posterior to the right. (E, F) TUNEL staining on transverse sections through E11.5 embryos at the level of the hindlimb bud
showing similar levels of apoptosis in control (E) and Fgf9−/− (F) hindlimbs; dorsal at the bottom, proximal to the left. (G, H) Control (G) and Fgf9−/− (H) H&E-
stained E12.5 longitudinal hindlimb sections showing similar condensation sizes for proximal and intermediate limb elements. z, zeugopod; s, stylopod. (I, J) Sox9 in
situ hybridization of nearby sections to panels G and H. (K, L) ColII in situ hybridization of nearby sections to panels G and H. (I–L) Dark-field images.
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avascular with relatively few hypertrophic chondrocytes (Figs.
4C, D). By E16.5 the primary ossification center had formed in
the control femur, while the shaft of the Fgf9−/− bone contained
an expanded zone of hypertrophic chondrocytes with a small
focus of vascularization and absent trabecular bone formation
(Figs. 4G, H). By E18.5 the ossification center in the Fgf9−/−
femur was well-developed with abundant blood vessels,
although the trabecular bone region was reduced in size (Figs.
4I, J). Delayed bone formation was not apparent in the inter-
mediate and distal elements of the Fgf9−/− limbs (Figs. 4E, F
and data not shown).
In vitro studies have shown that FGF9 can activate the c
splice forms of FGFRs 1, 2 and 3, FGFR4, and the b splice form
of FGFR3 (Ornitz et al., 1996; Zhang et al., 2006). In deve-
loping bone, Fgfrs 1 and 2 are expressed in the mesenchymal
condensation, immature and reserve zone chondrocytes, the
perichondrium/periosteum and various stages of osteoblast
development (Jacob et al., 2006; Ornitz and Marie, 2002; Yu et
al., 2003). Fgfr1 is also expressed in hypertrophic chondrocytes
and Fgfr3 is expressed in proliferating chondrocytes (Ornitz
and Marie, 2002) and mature osteoblasts (Xiao et al., 2004).
Since Fgf9 is widely expressed in the perichondrium/peri-
osteum, trabecular bone, surrounding muscle and soft tissue, it
can potentially interact with all three Fgfrs. To ascertain which
FGFR(s) could serve as the physiological receptor for FGF9, we
compared the histological phenotype from limbs of Fgfr3−/−
miceandfromconditionalknockoutmicelackingFgfr1(Fgfr1cko)
or Fgfr2 (Fgfr2cko) in osteochondroblast lineages with those
of Fgf9−/− mice. These studies revealed that Fgfr1cko miceexhibited a consistent delay in hypertrophic cartilage
differentiation at mid-embryonic stages (Fig. 4L), similar to
that observed in the Fgf9−/− mice, while Fgfr2cko mice (Fig.
4M) or Fgfr3−/− mice (Fig. 4N) did not exhibit his-
tomorphological alterations at this stage.
Delayed initiation of chondrocyte hypertrophy in Fgf9−/− mice
The narrowed zone of hypertrophic chondrocytes observed
in the Fgf9−/− femur at E15.5 (Figs. 4C, D) suggested that
chondrocyte maturation might be defective in proximal skeletal
elements. To examine chondrogenesis in the mutant limbs,
expression studies were performed for ColII, a marker of proli-
ferating chondrocytes, and type X collagen (ColX), a specific
marker of hypertrophic chondrocytes. At E14.5, ColII expres-
sion was present throughout the control femur, except in the
central region of the cartilage, where chondrocytes had under-
gone hypertrophy. Cells with downregulated ColII expression
showed high levels of ColX mRNA (Figs. 5A, C, E). In the
Fgf9−/− femur at the same stage, ColII expression was present
throughout the entire cartilage anlagen while ColX expression
was completely absent, indicating that chondrocytes had not yet
matured to the hypertrophic stage (Figs. 5B, D, F). A decrease
in the pool of proliferating chondrocytes available to undergo
hypertrophic differentiation could explain the observed delay in
chondrocyte maturation. BrdU incorporation studies to assess
cell proliferation rates at E13.5 and E14.5 showed a significant
reduction in proliferation of Fgf9−/− femoral chondrocytes at
E14.5 compared to control (Table 1). At E13.5, no significant
difference in proliferation was detected.
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ColX expression levels were similar between the control and
Fgf9−/− distal femoral growth plates (Figs. 5I–L); however, the
hypertrophic zone (HZ) height was significantly enlarged in the
Fgf9−/− femora (Figs. 5G, H, Table 2). In contrast, the hyper-
trophic zone height in the proximal tibia did not differ sig-
nificantly between Fgf9−/− and control mice (Table 2). The
expanded hypertrophic chondrocyte zone in the Fgf9−/− femur
could result from increased proliferation, in effect enlarging the
pool of precursor chondrocytes available to undergo hyper-
trophy, a reduction in the rate of loss of terminally differentiated
hypertrophic chondrocytes, or a delay in the initiation of
chondrocyte loss due to delayed formation of the primary
ossification center.
Ihh and PTHrP signaling are delayed during early
chondrogenesis in Fgf9−/− mice
Consistent with these findings, the patterns of expression for
Ihh, Ptc and Pth1r expression suggested delayed chondrocyte
differentiation in the Fgf9−/− femur at E14.5 (Fig. 6). For
example, Ihh is normally expressed in prehypertrophic chon-
drocytes of developing bone, which flank the centrally located
hypertrophic chondrocytes of the control femur in two distinct
zones at E14.5. In the Fgf9−/− cartilage, Ihh is expressed in the
prehypertrophic chondrocytes, but these cells are only found in
the center of the anlagen (Figs. 6C, D). Similarly, Ptc is nor-
mally expressed in proliferating and prehypertrophic chondro-
cytes and the perichondrium, while its expression is downre-
gulated in hypertrophic chondrocytes. In the control femur at
this stage, Ptc expression is evident in the perichondrium as
well as in the populations of proliferating and prehypertrophic
chondrocytes that flank the centrally located hypertrophic
chondrocytes. However, in the Fgf9−/− femur, expression of Ptc
appears diffusely throughout the cartilage anlagen and in the
perichondrium, with no central area of downregulation due to
the absence of mature hypertrophic chondrocytes (Figs. 6E, F).
Expression of Pth1r is barely detectable in the Fgf9−/− femur at
this stage (Figs. 6G, H), while it is easily detected in the control
prehypertrophic and hypertrophic chondrocyte populations. By
E18.5 (Figs. 6K–P), patterns and levels of Ihh, Ptc and Pth1rFig. 4. Histological analysis of Fgf9−/− hindlimbs. (A–F) H&E sections of
E15.5 humeri (A, B), femora (C, D) and tibiae (E, F). (A, C, E) control, (B, D, F)
Fgf9−/−. Note reduced area of vascular invasion in Fgf9−/− humerus. In Fgf9−/−
femur, the hypertrophic chondrocyte zone is shortened and no vascular invasion
of the cartilage is visible. Development of the Fgf9−/− tibia is similar to the
control indicating no developmental delay. (G, H) H&E staining of E16.5
control (G) and Fgf9−/− (H) femora. Note that the primary ossification center has
developed in the control bone while only the initial stages of vascular invasion
are apparent in Fgf9−/− bone. (I, J) H&E sections of E18.5 control (I) and
Fgf9−/− (J) femora. Ossification centers are now well-developed in control and
Fgf9−/− bones, but the Fgf9−/− femur is shorter and broader with decreased areas
of trabecular bone formation and an enlarged hypertrophic chondrocyte zone.
Trabecular bone regions are indicated with green brackets in panels G–J. (K–N)
H&E sections of E14.5–E14.75 control (K), Fgfr1cko (L), Fgfr2cko (M) and
Fgfr3−/− (N) femora showing a smaller hypertrophic chondrocyte zone in tissue
missing Fgfr1 but not Fgfr2 or Fgfr3.
Fig. 5. Expression of chondrocyte differentiation markers at E14.5 and E17.5. H&E staining of E14.5 (A, B) and E17.5 (G, H) femora. Type II collagen (ColII)
expression at E14.5 (C, D) and E17.5 (I, J). Type X collagen (ColX) expression at E14.5 (E, F) and E17.5 (K, L). Hypertrophic zone regions are indicated with green
brackets in panels A, G, H. A, C, E, G, I, K are sections from control littermates. Panels B, D, F, H, J, L are sections from Fgf9−/− mice.
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that chondrogenesis at later stages of bone development was not
significantly affected by loss of FGF9.
FGF9 promotes osteogenesis in the stylopod
The reduced area of Alizarin red-staining and delayed form-
ation of the primary ossification centers suggested abnormal
osteogenesis in Fgf9−/− mice. Consistent with our previous
findings, von Kossa staining showed abundant mineralization in
control bones but significantly decreased mineralization of both
trabecular and cortical regions in Fgf9−/− bones at E16.5 (Figs.
7A, B and data not shown). Defective osteoblastogenesis is one
potential cause for delayed bone formation in Fgf9−/− mice and
may be due to a deficiency in osteoblast progenitor cells or a
defect in osteoblast proliferation or maturation. To characterize
osteoblast development, the expression of osteoblast differentia-
tion markers, Runx2 (Cbfa1), Type I collagen (ColI), and Os-Table 1
Cell proliferation in E13.5 and E14.5 control and Fgf9−/− femora
Age Genotype n a BrdU+cells/0.01 mm2 P value
E13.5 +/+, +/− 7 34.4±1.7 ns
−/− 4 35.2±1.6
E14.5 +/+, +/− 6 28.0±2.2 b0.04
−/− 5 24.5±2.5
ns, not significant.
a n, number of animals examined.teocalcin were examined. Runx2 is expressed in osteoproge-
nitor cells in the perichondrium and in hypertrophic
chondrocytes. Similar levels of expression of Runx2 were
detected in control and Fgf9−/− perichondrium at E14.5,
indicating that similar numbers of osteoprogenitor cells were
present (Figs. 7E, F). However, ColI and Osteocalcin levels
were markedly decreased in the perichondrium/periosteum and
trabecular bone regions of Fgf9−/− mice from E16.5 to E18.5,
which suggested that there were fewer mature osteoblasts in the
absence of Fgf9 (Figs. 7G, H and data not shown). In vitro
osteoblast culture data suggest that FGF9 signaling may directly
stimulate osteogenic differentiation and matrix mineralization
in a stage-dependent manner (Fakhry et al., 2005; Jacob et al.,
2006; Valverde-Franco et al., 2004). Thus, FGF9 may function
to regulate osteoblast proliferation or differentiation by
signaling directly to FGFRs expressed in osteoblast lineages.
Alternatively, FGF9 could control the influx of osteoblasts into
the trabecular bone region.Table 2
Bone morphometric data
Growth plate Genotype n a HZ b height (mm) P value
Distal femur +/+, +/− 3 0.35±0.02 0.001
−/− 3 0.49±0.01
Proximal tibia +/+, +/− 3 0.46±0.03 0.18
−/− 3 0.50±0.03
a n, number of animals examined at E17.5–E18.5.
b Hypertrophic chondrocyte zone mean height (mm).
Fig. 6. Expression of Ihh, Ptc and Pth1r at E14.5 and E18.5. H&E staining of E14.5 (A, B) and E18.5 (I, J) femora. (C–H, K–P) Dark-field images. Ihh expression at
E14.5 (C, D) and E18.5 (K, L). Ptc expression at E14.5 (E, F) and E18.5 (M, N). Pth1r expression at E14.5 (G, H) and E18.5 (O, P). Panels A, C, E, G, I, K, M, O are
sections from control littermates. Panels B, D, F, H, J, L, N, P are sections from Fgf9−/− mice.
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To analyze the osteoclast populations in control and Fgf9−/−
femurs, in situ hybridization studies were performed with the
osteoclast-specific markers, matrix metalloproteinase 9 (MMP9)
and tartrate-resistant acid phosphatase (TRAP). At E16.5,
MMP9 expression was localized to the cartilage–bone interface
as well as to the trabecular region in control bones, whereas
MMP9 expression was markedly reduced in the Fgf9−/− femur,
with transcripts detectable only in the vascular invasion front of
the developing bone (Figs. 7I, J). TRAP expression at E16.5 and
TRAP staining at E17.5–E18.5 were similarly decreased in the
Fgf9−/− femur compared to control (Figs. 7K, L and data not
shown). These data indicate that loss of Fgf9 results in a
reduction in osteoclast cell populations in the perichondrium and
primary spongiosa of developing bone.
Delayed vascular invasion in Fgf9−/− femurs
Vascularization of the developing skeletal elements is a key
step in endochondral ossification, allowing the influx of osteo-
blast and osteoclast progenitors into the initially avascular car-tilaginous matrix surrounding hypertrophic chondrocytes
(Colnot et al., 2005; Zelzer and Olsen, 2005). Angiogenesis
of developing bone was ascertained by PECAM (CD31) immu-
nohistochemistry. At E16.5, blood vessels were present in the
perichondrium/periosteum and in the marrow cavity of control
femur, while in Fgf9−/− mice, blood vessels were clearly visible
in the perichondrium surrounding the femur cartilage but had
not yet invaded the future marrow cavity (Figs. 8A, B). These
data suggest that Fgf9 is important for promoting skeletal vas-
cularization and that the delayed osteogenesis in the proximal
limbs of Fgf9−/− mice may result from defects in angiogenesis.
Decreased VEGF signaling in Fgf9−/− mice
Vascular endothelial growth factor (VEGF) is essential for
blood vessel formation and chondrocyte maturation in the
developing skeleton (Maes et al., 2002; Ornitz, 2005; Zelzer et
al., 2002; Zelzer and Olsen, 2005). Vegf is expressed in the
perichondrium and subsequently in hypertrophic chondrocytes
and functions to promote vascularization of the cartilage anla-
gen. In Fgf9−/− mice, delayed vascular invasion may be due to
decreased VEGF signaling. To test this hypothesis, we exa-
Fig. 7. Osteoblast and osteoclast markers at E14.5 and E16.5. (A, B) von Kossa-stained E16.5 femora. (C, D) H&E-stained E14.5 femora. (E, F) Runx2/Cbfa1
expression at E14.5. (G, H) ColI expression at E16.5. (I, J)MMP9 expression at E16.5. (K, L) TRAP expression at E16.5. (E–L) Dark-field images. Panels A, C, E, G,
I, K are sections from control littermates. Panels B, D, F, H, J, L are sections from Fgf9−/− mice.
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(Figs. 8C–F). At E14.5, similar levels of Vegf expression were
observed in the perichondrium. However, in control bone, Vegf
was also expressed centrally in hypertrophic chondrocytes,
whereas in Fgf9−/− mice, there was little Vegf expression in thisFig. 8. Vascularization and expression of Vegf and Vegf receptors in the developing fem
hematoxylin showing abundant vascularization in control femur (A) compared with
field images showing Vegf expression at E14.5. Note Vegf expression in the center of c
Vegf transcripts are only detectable in the perichondrium (F). (G, H) H&E staining of
expression at E16.5. Panels A, C, E, G, I, K are sections from control littermates. Pregion. Vegf receptor (Vegfr) expression levels correlate with
the intensity of VEGF signaling (Barleon et al., 1997; Gerber
et al., 1999; Shen et al., 1998; Zelzer et al., 2002). At E16.5,
both Vegfr1 and Vegfr2 expression levels were decreased in the
perichondrium and diaphysis of Fgf9−/− femora compared tour. PECAM (CD31) immunohistochemistry (brown signal) counterstained with
Fgf9−/− femur (B) at E16.5. (C, D) H&E staining of E14.5 femora. (E, F) Dark-
ontrol cartilage anlagen (arrow in E) and in the perichondrium. In Fgf9−/− femur,
E16.5 femora. (I–L) Dark-field images showing Vegfr1 (I, J) and Vegfr2 (K, L)
anels B, D, F, H, J, L are sections from Fgf9−/− mice.
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age at E14.5 and reduced vascular invasion of the Fgf9−/−
hypertrophic zone (Figs. 8I–L).
Fgf9 induces Vegf expression and skeletal vascularization in
limb explant cultures
Analyses of Fgf9−/− limbs suggest that FGF9 promotes
vascular development by stimulating VEGF signaling in prox-
imal skeletal elements. To test whether FGF9 was sufficient to
induce Vegf expression, E14.5 forelimbs from mice hetero-
zygous for a ß-galactosidase-tagged allele of Vegf were cultured
with bovine serum albumin (BSA), FGF10 or FGF9. Vegf
expression levels were not affected by treatment with BSA or
FGF10, which signals to epithelial FGFR2b; however, Vegf
expression levels were upregulated in limbs treated with FGF9
(Figs. 9A–C). Cryosections revealed increased Vegf expression
in the thickened perichondrium and hypertrophic chondrocytes
of FGF9-treated explants (Figs. 9D–F). These data demonstrate
that FGF9 is sufficient to induce VEGF in skeletal tissue. Since
VEGF is an important stimulator of skeletal angiogenesis, these
data support the hypothesis that FGF9 regulates vascularization
of developing bone by positively regulating Vegf expression.Fig. 9. FGF9 induces Vegf expression and vascular development in limb explant cul
were cultured with BSA (A, D, G, J), FGF10 (B, E, H, K) or FGF9 (C, F, I, L). (A–C
(D–F) Frozen sections of boxed areas in panels A–C showing increased β-galactosid
chondrocytes of the explant cultured with FGF9 (asterisk in panel F). (G–I) PECAM i
panels A–C. Note marked increase in perichondrial vascularization of the explant cul
hematoxylin to show FGF9-induced perichondrial vascularization and thickening (aPECAM immunohistochemistry was performed on contralateral
cartilage explants to determine whether treatment with FGF9
could promote vascularization. Explants cultured with FGF10
did not show an increase in vascularization compared with the
BSA control. In contrast, explants cultured with FGF9 showed a
marked increase in perichondrial vascularization (Figs. 9G–L).
Discussion
Here we present evidence that FGF9 participates in multiple
steps of endochondral ossification to regulate skeletal develop-
ment in the proximal limb. Mice lacking FGF9 have rhizomelic
limb shortening, initiated at the earliest stages of skeletal
growth. In Fgf9−/− mice, this limb deformity is a consequence
of loss of Fgf9 expression in the muscle, perichondrium/
periosteum, trabecular bone and loose mesenchyme surround-
ing the developing bone rather than loss of Fgf9 expression in
the AER, since development of limb buds and mesenchymal
condensations was normal. Analysis of Fgf9−/− limbs revealed
that, in stylopod elements, loss of FGF9 function resulted in
decreased chondrocyte proliferation, delayed initiation of
chondrocyte hypertrophy and aberrant formation of mineralized
bone secondary to defects in skeletal angiogenesis.tures. E14.5 forelimb cartilage explants from heterozygous Vegf-LacZ embryos
) staining for β-galactosidase enzymatic activity as a measure of Vegf expression.
ase activity in the thickened perichondrium (arrow in panel F) and hypertrophic
mmunohistochemistry (brown signal) on contralateral explants to those shown in
tured with FGF9 (I). (J–K) Paraffin sections of panels G–H counterstained with
rrow in panel L).
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In the proximal limb elements of Fgf9−/− mice, the hyper-
trophic zone size was decreased at midgestation, suggesting that
FGF9 signaling is required for normal chondrocyte maturation.
A similar histological phenotype has been observed throughout
the skeleton in mice lacking FGF18. In vitro studies have shown
that both FGF9 and FGF18 are able to activate all FGFRs
expressed in bone (Ornitz et al., 1996; Zhang et al., 2006). To
determine which FGFR was transducing the FGF9 signal,
growth plate histology was examined from Fgfr3−/− mice and
from mice lacking FGFR1 or FGFR2 in skeletal lineages.
Only the Fgfr1cko mice showed a similar decrease in hyper-
trophic zone size at this stage, indicating that FGF9 likely
signals through FGFR1 to initiate hypertrophic chondrocyte
differentiation during very early stages of chondrogenesis.
The smaller zone of chondrocyte hypertrophy at early stages
in Fgf9−/− mice may be due to decreased chondrocyte proli-
feration at E14.5, which would result in fewer chondrocytes
available to undergo differentiation. Reduced proliferation was
also observed in Fgf18−/− mice (Liu et al., 2007). At earlier
stages of chondrogenesis, effects on proliferation in Fgf9−/−
proximal limbs may be partially masked by redundancy with
FGF18 (Davidson et al., 2005; Iwata et al., 2000; Liu et al.,
2002, 2007; Ohbayashi et al., 2002). In addition to direct
regulation of chondrocyte growth and differentiation by FGF
signaling, other pathways known to be important in chondro-
genesis, such as the IHH and PTHrP signaling pathways, may
also modulate chondrocyte proliferation in response to changes
in FGF signaling. During early chondrogenesis, IHH regulates
chondrocyte maturation through induction of PTHrP (St-
Jacques et al., 1999) and also promotes chondrocyte prolifera-
tion through a PTHrP-independent pathway (Karp et al., 2000).
In the stylopod elements of Fgf9−/− mice at E14.5, Ihh, Ptc and
Pth1r expression levels were decreased, suggesting that FGF9
may also regulate chondrogenesis indirectly through these
pathways. Reduced levels of Ihh were also observed at early
stages in Fgf18−/− limbs (Liu et al., 2007). Previous studies
showed that FGF18 and FGFR3 inhibited Ihh expression in
prehypertrophic chondrocytes at late embryonic and postnatal
stages (Liu et al., 2002, 2007; Naski et al., 1998). Our obser-
vations of the concomitant decreases in both Ihh expression and
chondrocyte proliferation suggest that FGF9 and FGF18 may
also regulate chondrocyte proliferation and differentiation indi-
rectly by regulating IHH signaling. In support of this model,
Iwata et al. (2000) observed increased chondrocyte proliferation
and increased Ptc expression at E15.5 in mice harboring an
Fgfr3 gain of function mutation.
FGF9 promotes skeletal vascularization and osteogenesis
In Fgf9−/− mice, abnormalities in Alizarin red and von Kossa
staining were consistent with decreased mineralization of the
femora, suggesting that FGF9 positively regulates osteogenesis
in the developing stylopod. Defective bone formation was fur-
ther confirmed by the observation that osteoblast and osteoclast
markers were downregulated in Fgf9−/− mice. These findingsmay be a result of earlier defects in chondrogenesis, or alter-
natively FGF9 may directly regulate osteogenesis, as has been
demonstrated by in vitro culture studies (Fakhry et al., 2005).
Osteoblasts are derived from mesenchymal progenitor cells that
reside in the perichondrium, while osteoclasts originate from
hematopoietic lineages. Although it is possible that loss of
FGF9 signaling results in independent effects on these two
distinct cell lineages, a simpler explanation for the reduced
numbers of osteoblasts and osteoclasts in the developing bone is
that skeletal angiogenesis, which is required for both of these
cell populations to gain entry into the avascular cartilaginous
tissue, is delayed in the absence of FGF9. In support of this
model, PECAM immunohistochemistry showed delayed vas-
cularization of Fgf9−/− stylopod elements. A delay in the
formation of the primary spongiosa could also explain the
increased hypertrophic zone size observed at late embryonic
stages since accumulation of hypertrophic chondrocytes has
been reported in several mouse models with impaired skeletal
angiogenesis and is thought to result from delayed removal
of terminally differentiated hypertrophic chondrocytes (Gerber
et al., 1999; Haigh et al., 2000; Vu et al., 1998).
Blood vessel formation is a complex process which is
orchestrated by multiple signaling pathways. Various angio-
genic factors, including FGF, VEGF, angiopoietins and IHH,
are involved in vascularization of the developing skeleton
(Colnot et al., 2005; Liu et al., 2007; Zelzer and Olsen, 2005).
Several explanations could account for the delayed vascular
invasion of the Fgf9−/− stylopod growth plates. FGF signaling
promotes growth of vascular endothelium (Auguste et al., 2003;
Kanda et al., 2004; Seghezzi et al., 1998) and could act directly
on endothelial cells to facilitate their invasion of the growth
plate. However, conditional inactivation of Fgfr1 and Fgfr2 in
endothelial cells did not affect skeletal development (KJL and
DMO, unpublished observation), suggesting that FGFs do not
signal directly to the endothelial cells in the developing growth
plate. FGF signaling can also promote Vegf expression, either
directly or indirectly through other signaling pathways (Kanda
et al., 2004; Lavine et al., 2006; Seghezzi et al., 1998).
Consistent with this possibility, Vegf expression was reduced in
the absence of FGF9. Additionally, in forelimb cartilage explant
cultures, FGF9 was sufficient to induce Vegf expression and to
stimulate cell proliferation and vascular growth within the
perichondrium (a prerequisite for invasion of the growth plate).
Mice lacking Fgfr3 showed reduced expression of Vegf in their
expanded zone of hypertrophic chondrocytes and impaired
blood vessel formation at the chondro-osseous junction
(Amizuka et al., 2004); however, Fgfr3−/− mice did not show
a delay in the formation of the primary ossification center
(Colvin et al., 1996). These data suggest that, during skeletal
development, FGF9 signals to FGFR1 and/or FGFR2 in the
perichondrium/periosteum to potentiate VEGF signaling and to
promote perichondrial angiogenesis. Additionally, FGF9 may
signal to FGFR3 in proliferating chondrocytes and/or to
FGFR1 in hypertrophic chondrocytes to upregulate VEGF
signaling within the growth plate. This source of VEGF would
stimulate vascularization of the hypertrophic cartilage and the
chondro-osseous junction once the primary ossification center
Fig. 10. Functional gradient model of FGF9 and FGF18 in the developing limb.
Levels of FGF9 function vary throughout the limb, with highest levels in the
stylopod and diminishing levels in more distal segments. In contrast, FGF18
function remains relatively constant throughout the stylopod, zeugopod and
autopod compartments.
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2005).
Gradient model for FGF9 and FGF18 in the developing limb
Three FGF ligands, FGFs 2, 9 and 18, have identified
physiological roles in skeletogenesis. FGF2 signaling affects
trabecular bone architecture but not the onset of ossification or
vascularization (Montero et al., 2000). Fgf9 and Fgf18 display
some overlap in their expression patterns and mice lacking
either FGF9 or FGF18 have delayed chondrogenesis, skeletal
vascularization and mineralization. However, loss of FGF9
causes a specific defect in the formation of the stylopod
elements despite the fact that Fgf9 is expressed throughout the
developing limb, while loss of FGF18 causes a more uniform
delay, affecting proximal, intermediate and distal compartments
of the developing limb (Liu et al., 2007). These differences may
occur because there is an increased dosage requirement of FGFs
for development of proximal versus distal limb elements or
because different FGF ligands exhibit different levels of activity
depending on their location. Based on our data, a model can be
proposed in which functional gradients of FGF9 and FGF18
activity modulate various aspects of skeletal development
along a proximal-distal axis. This model predicts, for example,
that a delayed vascularization phenotype observed in the
stylopod in Fgf9−/− embryos may become more severe in the
stylopod and extend more distally if one copy of Fgf18 is
removed. Alternatively, the Fgf18−/− phenotype may become
more severe if one copy of Fgf9 is removed. Preliminary
observations of these genetic crosses suggest that this type of
functional redundancy does occur (Fig. 10).
Another interesting feature of the Fgf9−/− phenotype is the
disproportionate shortening of the proximal skeletal elements
(rhizomelia). Rhizomelia is a prominent deformity seen in
patients with achondroplasia who harbor gain of function
mutations in Fgfr3. Interestingly, this proximal limb defect has
not been observed in mice with activating mutations in Fgfr3
(Chen et al., 1999, 2001; Iwata et al., 2001; Li et al., 1999;
Naski et al., 1998; Segev et al., 2000; Wang et al., 1999) but has
been observed postnatally in transgenic mice overexpressing
Fgf9 in cartilage (Garofalo et al., 2003). Furthermore, in
Fgfr3−/− mice, the limb overgrowth phenotype is only seen
beginning at late embryonic stages, whereas the rhizomelia
observed in Fgf9−/− mice occurs at earlier stages. Because
signaling through FGFR3 may have a biphasic response duringdevelopment, it is possible that loss of FGF9 would result in
increased proximal limb growth at postnatal stages. If this were
the case, specifically inhibiting FGF9 postnatally may provide a
therapeutic avenue for the treatment of achondroplasia.
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